Bronchopulmonary Dysplasia: An Update of Current Pharmacologic Therapies and New Approaches

Bronchopulmonary dysplasia (BPD) remains the most prevalent long-term morbidity of surviving extremely preterm infants and is associated with significant health care utilization in infancy and beyond. Recent advances in neonatal care have resulted in improved survival of extremely low birth weight (ELBW) infants; however, the incidence of BPD has not been substantially impacted by novel interventions in this vulnerable population. The multifactorial cause of BPD requires a multi-pronged approach for prevention and treatment. New approaches in assisted ventilation, optimal nutrition, and pharmacologic interventions are currently being evaluated. The focus of this review is the current state of the evidence for pharmacotherapy in BPD. Promising future approaches in need of further study will also be reviewed.

• Publication year

  2018

• Venue

  Clinical Medicine Insights: Pediatrics

• Publication date

  2018-12-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1179556518817322PMID 30574005PMCID 6295761
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study

  2020cited by this paper
• Sildenafil and Retinopathy of Prematurity in Preterm Infants with Bronchopulmonary Dysplasia

  2018cited by this paper
• Describing the Increase in Preterm Births in the United States, 2014-2016.

  2018cited by this paper
• Treatment of rat congenital diaphragmatic hernia with sildenafil and NS-304, selexipag's active compound, at the pseudoglandular stage improves lung vasculature.

  2018cited by this paper
• L-citrulline supplementation in the treatment of pulmonary hypertension associated with bronchopulmonary dysplasia in preterm infant: A case report

  2018cited by this paper
• Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation

  2018cited by this paper
• Long‐Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia

  2018cited by this paper
• Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study): statistical analysis plan

  2018cited by this paper
• Mesenchymal Stromal Cell Therapy for Respiratory Complications of Extreme Prematurity

  2018cited by this paper
• Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial

  2018cited by this paper
• Two‐Year Follow‐Up Outcomes of Premature Infants Enrolled in the Phase I Trial of Mesenchymal Stem Cells Transplantation for Bronchopulmonary Dysplasia

  2017cited by this paper
• The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1‐Year Corrected Age

  2017cited by this paper
• ‘Good things come in small packages’: Application of exosome-based therapeutics in neonatal lung injury

  2017cited by this paper
• Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

  2017cited by this paper
• Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

  2017cited by this paper
• Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm Infants

  2017cited by this paper
• Inhaled nitric oxide for respiratory failure in preterm infants.

  2017cited by this paper
• Revisiting the Definition of Bronchopulmonary Dysplasia: Effect of Changing Panoply of Respiratory Support for Preterm Neonates

  2017cited by this paper
• Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016

  2017cited by this paper
• Enteral vitamin A for reducing severity of bronchopulmonary dysplasia in extremely preterm infants: a randomised controlled trial

  2017cited by this paper
• Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age

  2017cited by this paper
• Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial.

  2017cited by this paper
• Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children under 1,251 g at Birth

  2017cited by this paper
• Laryngeal Mask Airway for Surfactant Administration in Neonates: A Randomized, Controlled Trial

  2017cited by this paper
• Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants.

  2017cited by this paper
• Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates.

  2017cited by this paper
• Effect of Inhaled Nitric Oxide on Survival Without Bronchopulmonary Dysplasia in Preterm Infants: A Randomized Clinical Trial

  2017cited by this paper
• Early erythropoiesis-stimulating agents in preterm or low birth weight infants.

  2017cited by this paper
• Systematic Review of Inhaled Bronchodilator and Corticosteroid Therapies in Infants with Bronchopulmonary Dysplasia: Implications and Future Directions

  2016cited by this paper
• Should we still use vitamin A to prevent bronchopulmonary dysplasia?

  2016cited by this paper
• Randomized Trial of Late Surfactant Treatment in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide.

  2016cited by this paper
• Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.

  2016cited by this paper
• Minimally Invasive Surfactant Therapy and Noninvasive Respiratory Support.

  2016cited by this paper
• Effect of Minimally Invasive Surfactant Therapy on Lung Volume and Ventilation in Preterm Infants.

  2016cited by this paper
• Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis

  2016cited by this paper
• Early inhaled budesonide for the prevention of bronchopulmonary dysplasia

  2016cited by this paper
• Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial.

  2016cited by this paper
• Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants.

  2016cited by this paper
• Randomized trial of laryngeal mask airway versus endotracheal intubation for surfactant delivery

  2016cited by this paper
• Not another steroid trial: early low-dose hydrocortisone in preterm infants.

  2016cited by this paper
• Inhaled Corticosteroids for Bronchopulmonary Dysplasia: A Meta-analysis

  2016cited by this paper
• Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants

  2016cited by this paper
• Association of Noninvasive Ventilation Strategies With Mortality and Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review and Meta-analysis.

  2016cited by this paper
• Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia.

  2016cited by this paper
• Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012.

  2015cited by this paper
• Inositol in preterm infants at risk for or having respiratory distress syndrome.

  2015cited by this paper
• The efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia

  2015cited by this paper
• Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome.

  2015cited by this paper
• Comparisons and Limitations of Current Definitions of Bronchopulmonary Dysplasia for the Prematurity and Respiratory Outcomes Program.

  2015cited by this paper
• Nonintubated Surfactant Application vs Conventional Therapy in Extremely Preterm Infants: A Randomized Clinical Trial.

  2015cited by this paper
• Nebulized pentoxifylline for reducing the duration of oxygen supplementation in extremely preterm neonates.

  2015cited by this paper
• Pulmonary Hypertension and Vascular Abnormalities in Bronchopulmonary Dysplasia.

  2015cited by this paper
• Bronchopulmonary Dysplasia Early Changes Leading to Long-Term Consequences

  2015cited by this paper
• Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia.

  2015cited by this paper
• Anti-Inflammatory Effect of Caffeine Is Associated with Improved Lung Function after Lipopolysaccharide-Induced Amnionitis

  2014cited by this paper
• Reducing the Incidence of Chronic Lung Disease in Very Premature Infants with Aminophylline

  2014cited by this paper
• Bronchopulmonary dysplasia: clinical perspective.

  2014cited by this paper
• Inhaled Bronchodilator Use for Infants with Bronchopulmonary Dysplasia

  2014cited by this paper
• Use of Inhaled Nitric Oxide in Preterm Infants

  2014cited by this paper
• Effects of less-invasive surfactant administration on oxygenation, pulmonary surfactant distribution, and lung compliance in spontaneously breathing preterm lambs

  2014cited by this paper
• Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial.

  2014cited by this paper
• Diuretic Exposure in Premature Infants from 1997 to 2011

  2014cited by this paper
• Prophylactic erythropoietin exacerbates ventilation‐induced lung inflammation and injury in preterm lambs

  2014cited by this paper
• Azithromycin and Other Macrolides for Prevention of Bronchopulmonary Dysplasia: A Systematic Review and Meta-Analysis

  2014cited by this paper
• The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25–28 weeks gestation

  2014cited by this paper
• Minimally invasive surfactant administration in preterm infants: a meta-narrative review.

  2014cited by this paper
• Pulmonary hypertension in bronchopulmonary dysplasia: Clinical findings, cardiovascular anomalies and outcomes

  2014cited by this paper
• Omega-3 Long-Chain Polyunsaturated Fatty Acids for Extremely Preterm Infants: A Systematic Review

  2014cited by this paper
• Surfactant Administration via Thin Catheter During Spontaneous Breathing: Randomized Controlled Trial

  2013cited by this paper
• Paediatric pulmonary hypertension and sildenafil: current practice and controversies

  2013cited by this paper
• Early lung development: lifelong effect on respiratory health and disease.

  2013cited by this paper
• Stem cell-based therapy for neonatal lung disease—it’s in the juice

  2013cited by this paper
• Pulmonary hypertension in bronchopulmonary dysplasia.

  2013cited by this paper
• Hydrocortisone vs. dexamethasone treatment for bronchopulmonary dysplasia and their effects on general movements in preterm infants

  2012cited by this paper
• Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants.

  2012cited by this paper
• L-citrulline Prevents Alveolar and Vascular Derangement in a Rat Model of Moderate Hyperoxia-induced Lung Injury

  2012cited by this paper
• Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure

  2012cited by this paper
• Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension

  2012cited by this paper
• Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits?

  2012cited by this paper
• Decrease in Incidence of Bronchopulmonary Dysplasia with Erythropoietin Administration in Preterm Infants: A Retrospective Study

  2012cited by this paper
• Outcome of extremely low gestational age newborns after introduction of a revised protocol to assist preterm infants in their transition to extrauterine life

  2012cited by this paper
• Preliminary Evaluation of a New Technique of Minimally Invasive Surfactant Therapy

  2012cited by this paper
• Arginyl-glutamine dipeptide or docosahexaenoic acid attenuate hyperoxia-induced lung injury in neonatal mice.

  2012cited by this paper
• Preliminary evaluation of a new technique of minimally invasive surfactant therapy

  2012cited by this paper
• Pentoxifylline and prevention of hyperoxia-induced lung ­injury in neonatal rats

  2012cited by this paper
• Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease.

  2011cited by this paper
• Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease.

  2011cited by this paper
• Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease.

  2011cited by this paper
• NIH Consensus Development Conference Statement: Inhaled Nitric-Oxide Therapy for Premature Infants

  2011cited by this paper
• Decreased postnatal docosahexaenoic and arachidonic acid blood levels in premature infants are associated with neonatal morbidities.

  2011cited by this paper
• Systemic hydrocortisone to prevent bronchopulmonary dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial

  2011cited by this paper
• Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial.

  2011cited by this paper
• Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome.

  2011cited by this paper
• Clarithromycin in Preventing Bronchopulmonary Dysplasia in Ureaplasma urealyticum–Positive Preterm Infants

  2011cited by this paper
• Serial Measurements of Lung Function in a Cohort of Young Children With Bronchopulmonary Dysplasia

  2010cited by this paper
• Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia

  2010cited by this paper
• Preliminary evaluation of a new technique of minimally invasive surfactant therapy

  2010cited by this paper
• Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.

  2010cited by this paper
• Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial.

  2010cited by this paper
• Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats.

  2009cited by this paper

• Aerosol inhalation of dimeric artesunate phospholipid-conjugated liposomes ameliorates inflammation, fibrosis, and ferroptosis in neonatal mice with hyperoxia-induced lung injury

  2025cites this paper
• A Novel Model for Simultaneous Evaluation of Hyperoxia-Mediated Brain and Lung Injury in Neonatal Rats

  2025cites this paper
• TrkB Signaling Promotes Alveolar Capillary Angiogenesis Following Perinatal Hyperoxic Damage.

  2025cites this paper
• Evaluation of Prophylactic Caffeine Therapy in Neonatal Bronchopulmonary Dysplasia and Related Acute Comorbidities Running title: Prophylactic caffeine therapy in neonatal bronchopulmonary dysplasia

  2025cites this paper
• Diuretics use in the management of bronchopulmonary dysplasia in preterm infants: A systematic review

  2024cites this paper
• L-Citrulline in Neonates: From Bench to Bed Side

  2024cites this paper
• miRNA Signatures in Bronchopulmonary Dysplasia: Implications for Biomarkers, Pathogenesis, and Therapeutic Options

  2024cites this paper
• Development of a bronchopulmonary dysplasia nutrition focused physical examination tool: A modified Delphi study

  2024cites this paper
• Respiratory management of established severe bronchopulmonary dysplasia.

  2023cites this paper
• Furin Regulates the Alveolarization of Neonatal Lungs in a Mouse Model of Hyperoxic Lung Injury

  2023cites this paper
• Budesonide and surfactant combination for treatment of respiratory distress syndrome in preterm neonates and evaluation outcomes

  2023cites this paper
• Vascular Endothelial Growth Factor as Molecular Target for Bronchopulmonary Dysplasia Prevention in Very Low Birth Weight Infants

  2023cites this paper
• Predictive and Diagnostic Values of Systemic Inflammatory Indices in Bronchopulmonary Dysplasia

  2023cites this paper
• Nutrition-based implications and therapeutics in the development and recovery of Bronchopulmonary dysplasia.

  2023cites this paper
• L-citrulline attenuates lipopolysaccharide-induced inflammatory lung injury in neonatal rats

  2023cites this paper
• A Paternal Fish Oil Diet Preconception Reduces Lung Inflammation in a Toxicant-Driven Murine Model of New Bronchopulmonary Dysplasia

  2023cites this paper
• Effects of early vitamin D supplementation on the prevention of bronchopulmonary dysplasia in preterm infants

  2022cites this paper
• Headway and the remaining hurdles of mesenchymal stem cells therapy for bronchopulmonary dysplasia

  2022cites this paper
• Bronkopulmoner Displazi Tanısı ile İzlenen Hastaların Akciğer Manyetik Rezonans Görüntülemelerinin Değerlendirilmesi

  2022cites this paper
• Role of endoplasmic reticulum stress in impaired neonatal lung growth and bronchopulmonary dysplasia

  2022cites this paper
• Diagnostic efficacy of targeted high-throughput sequencing for lower respiratory infection in preterm infants.

  2022cites this paper
• Perinatal Hyperoxia and Developmental Consequences on the Lung-Brain Axis

  2022cites this paper
• Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?

  2022cites this paper
• Landscape analysis for a neonatal disease progression model of bronchopulmonary dysplasia: Leveraging clinical trial experience and real-world data

  2022cites this paper
• Developing a machine learning-based tool to extend the usability of the NICHD BPD Outcome Estimator to the Asian population

  2022cites this paper
• All trans-retinoic acid modulates hyperoxia-induced suppression of NF-kB-dependent Wnt signaling in alveolar A549 epithelial cells

  2022cites this paper
• Upregulating carnitine palmitoyltransferase 1 attenuates hyperoxia-induced endothelial cell dysfunction and persistent lung injury

  2022cites this paper
• Bronchopulmonary dysplasia with focus on early prediction and treatment: a narrative review

  2021cites this paper
• Description of a Nutrition Screening and Assessment Tool and Associations with Clinical Outcomes in Preterm Newborns.

  2021cites this paper
• Use of diuretics in the neonatal period

  2021cites this paper
• A Shift from Glycolytic and Fatty Acid Derivatives toward One-Carbon Metabolites in the Developing Lung During Transitions of the Early Postnatal Period.

  2021cites this paper
• Hypochloremia Secondary to Diuretics in Preterm Infants: Should Clinicians Pay Close Attention?

  2021influential citation
• Therapeutic Effects of Mesenchymal Stromal Cell-Derived Small Extracellular Vesicles in Oxygen-Induced Multi-Organ Disease: A Developmental Perspective

  2021cites this paper
• Lung recruitment improves the efficacy of intubation-surfactant-extubation treatment for respiratory distress syndrome in preterm neonates, a randomized controlled trial

  2021cites this paper
• A clinical study on plasma biomarkers for deciding the use of adjuvant corticosteroid therapy in bronchopulmonary dysplasia of premature infants

  2021cites this paper
• Postnatal diuretics, weight gain and home oxygen requirement in extremely preterm infants

  2021cites this paper
• Management of bronchopulmonary dysplasia: strategies to prevent short- and long-term complications following discharge from the NICU

  2021cites this paper
• Metabolic dysregulation in bronchopulmonary dysplasia: Implications for identification of biomarkers and therapeutic approaches

  2021cites this paper
• Mesenchymal Stem Cells: Potential Therapeutic Prospect of Paracrine Pathways in Neonatal Infection.

  2021cites this paper
• Dexamethasone Alters Tracheal Aspirate T-Cell Cytokine Production in Ventilated Preterm Infants

  2021cites this paper
• An Introduction to Advanced Lung Disease

  2021cites this paper
• Comparison of Multivariable Logistic Regression and Machine Learning Models for Predicting Bronchopulmonary Dysplasia or Death in Very Preterm Infants

  2021cites this paper
• Role of the LRP1-pPyk2-MMP9 pathway in hyperoxia-induced lung injury in neonatal rats.

  2021cites this paper
• Late surfactant replacement therapy and its efficacy on severe bronchopulmonary dysplasia in National Children Hospital

  2021cites this paper
• Under Pressure: “Just Right” is a Moving Target

  2021cites this paper
• Risk Factors for Foster Care Placement in Patients with Bronchopulmonary Dysplasia

  2021cites this paper
• A Microfluidic System to Measure Neonatal Lung Compliance Over Late Stage Development as a Functional Measure of Lung Tissue Mechanics.

  2020cites this paper
• The Role of LncRNA H19 in MAPK Signaling Pathway Implicated in the Progression of Bronchopulmonary Dysplasia

  2020cites this paper
• The First Allogeneic Transplantation of Human Umbilical Cord-derived Mesenchymal Stem/stromal Cells for Bronchopulmonary Dysplasia: Preliminary Outcomes in Four Vietnamese Infants

  2020cites this paper
• Advancing Therapeutic Development for Pulmonary Morbidities Associated with Preterm Birth

  2020cites this paper
• A Meta-Analysis of the Effects and Safety of Pulmonary Surfactants Combined with Budesonide in Bronchopulmonary Dysplasia

  2020cites this paper
• Exogenous Surfactant as a Pulmonary Delivery Vehicle for Budesonide In Vivo

  2020cites this paper
• Allogeneic administration of human umbilical cord-derived mesenchymal stem/stromal cells for bronchopulmonary dysplasia: preliminary outcomes in four Vietnamese infants

  2020cites this paper
• Proteomic analysis of sex differences in hyperoxic lung injury in neonatal mice

  2020cites this paper
• Amniotic fluid and breast milk: a rationale for breast milk stem cell therapy in neonatal diseases

  2020cites this paper
• Attenuation of Hyperoxic Lung Injury in Newborn Thioredoxin-1-Overexpressing Mice through the Suppression of Proinflammatory Cytokine mRNA Expression

  2020cites this paper
• Bronchopulmonary dysplasia predicted at birth by artificial intelligence

  2020cites this paper
• Factors Associated with Clinical Response to Low-Dose Dexamethasone Therapy for Bronchopulmonary Dysplasia in Very Low Birth Weight Infants

  2020cites this paper
• A case of near-fatal bronchospasm in a child with severe bronchopulmonary dysplasia during tracheostomy

  2020cites this paper
• Erythropoietin treatment is associated with a reduction in moderate to severe bronchopulmonary dysplasia in preterm infants. A regional retrospective study.

  2019cites this paper
• Meta-analysis of the efficacy of pulmonary surfactants combined with budesonide for the prevention of bronchopulmonary dysplasia

  2019cites this paper
• Mesenchymal Stem/Stromal Cell Therapy for Bronchopulmonary Dysplasia in the Neonatal Intensive Care Unit

  2019cites this paper
• Inhibition of microRNA-29a alleviates hyperoxia-induced bronchopulmonary dysplasia in neonatal mice via upregulation of GAB1

  2019cites this paper
• Stem-cell therapy for bronchopulmonary dysplasia.

  2019cites this paper
• Decorin Secreted by Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Induces Macrophage Polarization via CD44 to Repair Hyperoxic Lung Injury

  2019cites this paper
• Phenotypic overlap in neonatal respiratory morbidity following preterm premature rupture of membranes versus spontaneous preterm labor

  2019cites this paper
• Evaluation of Lung Magnetic Resonance Imaging of Patients Followed Up With Bronchopulmonary Dysplasia Bronkopulmoner Displazi Tanısı ile İzlenen Hastaların Akciğer Manyetik Rezonans Görüntülemelerinin Değerlendirilmesi

  year unknowncites this paper